Vittorio Mena
Corneal and Contact Management · Fairview, NJNPI 1942698717
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Alcon accounts for 61.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $19,413 and has fallen 69.5% since, to $5,930 in 2025. Among corneal and contact management clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $283.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$33K
- Visioneering Technologies, Inc.$7K
- Coopervision Inc.$5K
- Bausch & Lomb Americas Inc.$5K
- AbbVie$969
- Tarsus Pharmaceuticals, Inc.$543
- plus $2K from 10 others
What the payments were for
- Consulting fees$23,30744%
- Speaking & faculty fees$13,51725%
- Travel & lodging$7,30714%
- Food & beverage$8,93817%
- Entertainment$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 90 | $32,823 |
| Visioneering Technologies, Inc. | 16 | $7,281 |
| Coopervision Inc. | 19 | $5,131 |
| Bausch & Lomb Americas Inc. | 15 | $4,600 |
| AbbVie(2 entities) | 12 | $969 |
| Tarsus Pharmaceuticals, Inc. | 12 | $543 |
| Glaukos Corporation | 3 | $487 |
| Dompe US, Inc. | 9 | $421 |
| Sun Pharmaceutical Industries Inc. | 2 | $155 |
| Harrow Eye, LLC | 1 | $149 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $124 |
| Eyevance Pharmaceuticals LLC | 1 | $122 |
| Johnson & Johnson Vision Care, Inc. | 1 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $111 |
| Shire North American Group Inc | 2 | $33 |
| Optos, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$22,258
- DAILIES TOTAL1$16,177
- Precision 1$10,702
- MiSight Contact Lens$4,613
- DAILIES$928
- MIEBO$523
- Precision7$497
- VYZULTA$397
- XIIDRA$373
- CE-marked KXLA system$275
- TRYPTYR$270
- XDEMVY$264
- LUMIGAN$246
- RESTASIS$246
- VEVYE$149
- ILUX$126
- BIOTRUE$124
- ULTRA$124
- BIOTRUE ONE DAY$124
- LOTEMAX SM$124
How this compares
$53,099 in reported general payments places this provider in the 95th percentile of 45 corneal and contact management providers in New Jersey.
See all corneal and contact management providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 16 | $15,655 |
| LumiganBimatoprost | 14 | $4,675 |
| Prednisolone Acetate | 39 | $1,209 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $969 | $20,33030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 corneal and contact management providers in New Jersey.
Other corneal and contact management in Fairview
- Bradford RippsLake Hopatcong$94K
- Kenneth DanielsLambertville$14K
- Thomas ConroyBloomfield$9K
- Alan SchlusselWest Orange$8K
- Danica YangCranford$7K
- Daniel IsaacCherry Hill$5K
- Amy SteinParamus$4K
- Paul DifioreMount Laurel$3K
- Jeffrey CaseFreehold$3K
- Saras RustagiWest New York$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.